Related Articles
Neutropenia as a prognostic factor and safety of second‑line therapy with S‑1 for advanced or recurrent pancreatic cancer
Effect of the timing of discontinuation of last‑line chemotherapy on patient prognosis in advanced and recurrent gastric cancer
First-line single-agent chemotherapy for patients with recurrent or metastatic gastric cancer with poor performance status
Safety evaluation of lenvatinib treatment after atezolizumab plus bevacizumab therapy for patients with unresectable liver cancer: A comparison of lenvatinib as 1st‑ or 2nd‑line treatment
Angiogenesis inhibitor therapies for advanced renal cell carcinoma: Toxicity and treatment patterns in clinical practice from a global medical chart review